Invesco
CADL icon

Invesco’s Candel Therapeutics CADL Stock Holding History

Invesco’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$388K Buy
37,713
+16,806
+80% +$127K ﹤0.01% 3343
2026
Q1 		$102K Buy
20,907
+5,868
+39% +$31.9K ﹤0.01% 3623
2025
Q4 		$85K Buy
15,039
+3,380
+29% +$18.2K ﹤0.01% 3652
2025
Q3 		$59.5K Buy
11,659
+402
+4% +$2.32K ﹤0.01% 3735
2025
Q2 		$57K Buy
11,257
+844
+8% +$4.34K ﹤0.01% 3712
2025
Q1 		$58.8K Buy
+10,413
New +$85.1K ﹤0.01% 3686

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Invesco's CADL Position: Q2 2026 in Review

Invesco increased its Candel Therapeutics (CADL) stake by 80% in Q2 2026, buying an estimated $127K and bringing the position to 37,713 shares worth $388K. The position accounts for ﹤0.01% of the portfolio, ranked #3343.

Invesco first reported a position in CADL in Q1 2025 and has held it in 6 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Invesco held 37,713 shares of Candel Therapeutics worth $388K as of Q2 2026.
  • Invesco bought 16,806 Candel Therapeutics shares in Q2 2026, an estimated $127K.
  • Candel Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3343 holding.
  • Invesco first reported a position in Candel Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.